Business
Humacyte announces Symvess™ ECAT Approval from U.S. Defense Logistics Agency
Electronic Catalog listing approval makes Symvess available to healthcare professionals at U.S. Department of Defense and U.S. Department of Veterans Affairs facilitiesDURHAM, N.C., July 08, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced today that Symvess has been awarded Electronic Catalog (ECAT) listing approval from the U.S. Defense Logistic
About this update from Humacyte, Inc.
[{"type":"image","alt":"Humacyte, Inc","displaySize":"","headline":null,"caption":"Humacyte, Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":57,"url":"https://media.zenfs.com/en/globenewswire.com/6664e34870555953d37f7abc79cd102e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/trBSY4KWXHpBRzQ_5qCqbw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTgwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/6664e34870555953d37f7abc79cd102e","width":300,"height":57}},"lazy":false},{"type":"text","content":"Electronic Catalog listing approval makes Symvess available to healthcare professionals at U.S. Department of Defense and U.S. Department of Veterans Affairs facilities","length":168,"tagName":"p"},{"type":"text","content":"DURHAM, N.C., July 08, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced today that Symvess has been awarded Electronic Catalog (ECAT) listing approval from the U.S. Defense Logistics Agency. ECAT is an internet system that provides the Department of Defense (DOD) and other federal agencies with access to manufacturers’ and distributors’ products. The approval makes Symvess available to healthcare professionals treating military service members, veterans, and other patients receiving care at DOD and U.S. Department of Veterans Affairs facilities.","length":702,"tagName":"p"},{"type":"text","content":"Symvess (acellular tissue engineered vessel-tyod) was approved in the extremity vascular trauma indication by the Food and Drug Administration (FDA) in December 2024.","length":166,"tagName":"p"},{"type":"text","content":"“We are pleased that Symvess is now listed in the ECAT system, making the product more readily available to healthcare professionals treating military personnel and their families,” said Dr. Laura Niklason, President and CEO of Humacyte, Inc. “We have received positive feedback in our interactions with a number of DOD hospitals, and we look forward to making Symvess available to more patients in need.”","length":410,"tagName":"p"},{"type":"text","content":"For uses other than the FDA approval in the extremity vascular trauma indication, the ATEV is an investigational product and has not been approved for use or sale by the FDA or any oth...